A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
A phase 2 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, now recruiting.
Overview
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer is a phase 2 interventional study registered as NCT06567782 by GlaxoSmithKline, with 120 participants planned, started 2025-02-18 and due to reach its primary completion in 2026-11-23. Interventions recorded: Dostarlimab and CAPEOX.
Similar pages
not linked directly; found by shared links- TrialStudy of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Shares Dostarlimab, GSK, Colorectal cancer and the tag pipeline.
- TrialA Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
Shares Dostarlimab, GSK, Colorectal cancer and the tag pipeline.
- TrialA Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares GSK, Colorectal cancer and the tag pipeline.
- TrialA Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Shares Dostarlimab, GSK and the tag pipeline.